Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm
Blood · 29.10.2026 · 148 (18) · 2229-2238
DOI: 10.1182/blood.2026033906 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 29.10.2026. Verfasst von Andrew A Lane und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Blastic Plasmacytoid Dendritic Cell Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan, aggressive hematologic malignancy characterized by high CD123 expression. Tagraxofusp (TAG), a CD123-directed toxin, is the first approved therapy. Prior studies demonstrated BPDCN dependence on BCL2, sensitivity to venetoclax (VEN), and reversal of TAG resistance with azacitidine (AZA). We conducted a phase 2 study evaluating combination therapy with TAG, AZA, and VEN in patients with BPDCN. Patients with previously untreated (1L) or relapsed/refractory (R/R) BPDCN received 28-day cycles of AZA (75 mg/m2 on days 1-7), VEN (400 mg on days 1-21), and TAG (12 μg/kg on days 4-6). Eligibility followed TAG guidelines to mitigate risk of capillary leak syndrome (CLS). Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range, 21-81). Composite complete remission (composed of: complete remission [CR], CR with incomplete count recovery, and CR clinical) rates were 88% in 1L and 64% in R/R cohorts. Median duration of response was not reached in 1L and was 7.2 months in R/R patients. CLS occurred in 15% of patients, most were grade 2. In the 1L cohort, median overall survival (OS) and progression-free survival (PFS) were not reached; the 2-year OS was 65% and 2-year PFS was 53%. Median OS in R/R patients was 8.4 months. A high proportion of patients proceeded to allogeneic stem cell transplantation in remission (63% in 1L, including 10/11 patients aged ≤75 years; 55% in R/R). TAG-AZA-VEN is highly active in both 1L and relapsed BPDCN with a predictable and manageable safety profile, supporting its use as a new therapeutic option. This trial was registered at www.clinicaltrials.gov as #NCT03113643.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
ORCID-Profile: Andrew A Lane, Marlise R Luskin, Nicole R LeBoeuf, Jacqueline S Garcia, Shai Shimony, Naval Daver, Marina Y Konopleva, Naveen Pemmaraju
Zitieren
APA
Lane, A. A., Luskin, M. R., Keating, J., LeBoeuf, N. R., Garcia, J. S., Shimony, S., Leonard, R., Goodpaster, A., Nguyen, T. T., Galinsky, I., Eberly-Puleo, A., Daver, N., Jain, N., Garcia-Manero, G., Kantarjian, H., Konopleva, M. Y., Stein, A., & Pemmaraju, N. (2026). Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. Blood, 148(18), 2229-2238. https://doi.org/10.1182/blood.2026033906
Vancouver
Lane AA, Luskin MR, Keating J, LeBoeuf NR, Garcia JS, Shimony S, et al. Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. Blood. 2026;148(18):2229-2238. doi:10.1182/blood.2026033906
BibTeX
@article{Lane2026,
author = {Lane, Andrew A and Luskin, Marlise R and Keating, Julia and LeBoeuf, Nicole R and Garcia, Jacqueline S and Shimony, Shai and Leonard, Rebecca and Goodpaster, Adon and Nguyen, Theresa T and Galinsky, Ilene and Eberly-Puleo, Ashleigh and Daver, Naval and Jain, Nitin and Garcia-Manero, Guillermo and Kantarjian, Hagop and Konopleva, Marina Y and Stein, Anthony and Pemmaraju, Naveen},
title = {Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm},
journal = {Blood},
year = {2026},
volume = {148},
number = {18},
pages = {2229--2238},
doi = {10.1182/blood.2026033906}
}
EUVIMED